Reduced step dual path immunoassay device and method

Information

  • Patent Grant
  • 8603835
  • Patent Number
    8,603,835
  • Date Filed
    Thursday, February 10, 2011
    13 years ago
  • Date Issued
    Tuesday, December 10, 2013
    11 years ago
Abstract
Test cells have a first sorbent strip with a sample receiving location and defining a first migration path, a distinct second sorbent strip which receives buffer solution and at least partially defines a second migration path distinct from and elongated relative to the first migration path, conjugate supported by the second strip, a test site located at a junction of the first and second strips and having an immobilized ligand-binding mechanism, and a divider which directs a first amount of the buffer to the first strip to move the sample to the test site and a second amount to the second strip to move the conjugate to the test site. The first and second migration paths have first and second lengths chosen so that ligand in the sample reaches the test site and binds to the immobilized ligand-binding mechanism prior to the conjugate reaching the test site.
Description
RELATED APPLICATIONS

This application relates to PCT/US2006/008688 filed Mar. 10, 2006 published as WO 2006/099191 A2, U.S. Ser. No. 11/908,071 filed Sep. 7, 2007, and U.S. Ser. No. 61/338,303 filed Feb. 16, 2010 all of which are hereby incorporated by reference herein in their entireties.


BACKGROUND OF THE INVENTION

1. Field of the Invention


This invention relates broadly to immunoassay devices and the methods for their use. More particularly, this invention relates to chromatographic rapid test strips for detection of a ligand in a body fluid.


2. State of the Art


Many types of ligand-receptor assays have been used to detect the presence of various substances, often generally called ligands, in body fluids such as blood, urine, or saliva. These assays involve antigen antibody reactions, synthetic conjugates comprising radioactive, enzymatic, fluorescent, or visually observable polystyrene or metal sol tags, and specially designed reactor chambers. In all these assays, there is a receptor, e.g., an antibody, which is specific for the selected ligand or antigen, and a means for detecting the presence, and in some cases the amount, of the ligand-receptor reaction product. Some tests are designed to make a quantitative determination, but in many circumstances all that is required is a positive/negative qualitative indication. Examples of such qualitative assays include blood typing, most types of urinalysis, pregnancy tests, and AIDS tests. For these tests, a visually observable indicator such as the presence of agglutination or a color change is preferred.


Even the qualitative assays must be very sensitive because of the often small concentration of the ligand of interest in the test fluid. False positives can also be troublesome, particularly with agglutination and other rapid detection methods such as dipstick and color change tests. Because of these problems, so-called “sandwich” assays and other sensitive detection mechanisms which use metal sols or other types of colored particles have been developed.


In a “sandwich” assay, a target analyte such as an antigen is “sandwiched” between a labeled antibody and an antibody immobilized onto a solid support. The assay is read by observing the presence and/or amount of bound antigen-labeled antibody complex. In a “competition” immunoassay, antibody bound to a solid surface is contacted with a sample containing an unknown quantity of antigen analyte and with labeled antigen of the same type. The amount of labeled antigen bound on the solid surface is then determined to provide an indirect measure of the amount of antigen analyte in the sample.


Because these and other assays can detect both antibodies and antigens, they are generally referred to as immunochemical ligand-receptor assays or simply immunoassays.


Solid phase immunoassay devices, whether of the sandwich or competition type, provide sensitive detection of an analyte in a biological fluid sample such as blood, urine, or saliva. Solid phase immunoassay devices incorporate a solid support to which one member of a ligand-receptor pair, usually an antibody, antigen, or hapten, is bound. Common early forms of solid supports were plates, tubes, or beads of polystyrene which were well known from the fields of radioimmunoassay and enzyme immunoassay. In the last decade, a number of porous materials such as nylon, nitrocellulose, cellulose acetate, glass fibers, and other porous polymers have been employed as solid supports.


A number of self-contained immunoassay kits using porous materials as solid phase carriers of immunochemical components such as antigens, haptens, or antibodies have been described. These kits are usually dipstick, flow-through, or migratory in design.


In the more common forms of dipstick assays, as typified by home pregnancy and ovulation detection kits, immunochemical components such as antibodies are bound to a solid phase. The assay device is “dipped” for incubation into a sample suspected of containing unknown antigen analyte. Enzyme-labeled antibody is then added, either simultaneously or after an incubation period. The device is then washed and inserted into a second solution containing a substrate for the enzyme. The enzyme-label, if present, interacts with the substrate, causing the formation of colored products which either deposit as a precipitate onto the solid phase or produce a visible color change in the substrate solution.


Flow-through type immunoassay devices were designed to obviate the need for extensive incubation and cumbersome washing steps associated with dipstick assays. Valkirs et al., U.S. Pat. No. 4,632,901, disclose a device comprising antibody (specific to a target antigen analyte) bound to a porous membrane or filter to which is added a liquid sample. As the liquid flows through the membrane, target analyte binds to the antibody. The addition of sample is followed by addition of labeled antibody. The visual detection of labeled antibody provides an indication of the presence of target antigen analyte in the sample.


Korom et al., EP-A 0 299 359, discloses a variation in the flow-through device in which the labeled antibody is incorporated into a membrane which acts as a reagent delivery system.


The requirement of multiple addition and washing steps with dipstick and flow-through type immunoassay devices increases the likelihood that minimally trained personnel and home users will obtain erroneous assay results.


In migration type assays, a membrane is impregnated with the reagents needed to perform the assay. An analyte detection zone is provided in which labeled analyte is bound and assay indicia is read. See, for example, Tom et al., U.S. Pat. No. 4,366,241, and Zuk, et al. U.S. Pat. No. 4,596,275. The sensitivity of migration type assays is frequently reduced, however, by the presence or formation in the sample of undesirable solid components which block the passage of labeled analyte to the detection zone. Assay sensitivity also declines when migration assay devices are flooded with too much liquid sample.


Migration assay devices usually incorporate within them reagents which have been attached to colored labels (i.e., conjugates), thereby permitting visible detection of the assay results without addition of further substances. See, for example, Bernstein, U.S. Pat. No. 4,770,853. Among such labels are gold sol particles such as those described by Leuvering in U.S. Pat. No. 4,313,734, dye sol particles such as described in U.S. Pat. No. 4,373,932 by Gribnau et al., dyed latex such as described by May et al., WO 88/08534, and dyes encapsulated in liposomes by Campbell et al., U.S. Pat. No. 4,703,017. These colored labels are generally limited in terms of the immobilization methods which are suitable. Moreover, they require a relatively large amount of ligand molecule and can involve expensive reagents, thereby adding to the cost.


The “Related Applications” set forth above overcome many deficiencies of the prior art by providing “dual path” immunoassays which are highly sensitive, extremely reliable, accurate and inexpensive rapid detection devices. Generally, the dual path immunoassays include a first sorbent material having a first location for receiving a buffer solution (in the case of a dry conjugate system) or a conjugate solution (in the case of a liquid conjugate system) with the first sorbent material defining a first horizontal flow path, a second sorbent material having a second location for receiving a sample with the second sorbent material defining a second horizontal flow path distinct from the first flow path, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc. located in a test zone at a junction of the first and second sorbent materials.


Various types of samples are effectively tested using the duel path immunoassays, including but not limited to whole blood, blood serum, urine, sputum, saliva, and feces. For most samples it is common to utilize buffer solution to cause the sample to flow along the second sorbent material. Thus, one method of using a dual path immunoassays involves (1) depositing a sample at the (second) location for receiving the sample, (2) depositing buffer solution at the same location of the sample, (3) waiting a period of time sufficient to permit the sample to reach the test zone, (4) after waiting, depositing additional buffer solution at the (first) location for receiving the buffer solution such that the additional buffer solution causes the conjugate to flow to the test zone, and (5) inspecting the test zone to determine whether the test is positive or negative.


SUMMARY OF THE INVENTION

According to one aspect of the invention, a rapid detection dual path immunoassay device is provided that requires fewer steps to use than the previous dual path immunoassay devices.


According to another aspect of the invention, a dual path immunoassay device is provided that is simple to use and provides accurate results.


In one embodiment, a dry conjugate dual path immunoassay device system is provided and includes a test cell with a first location for receiving a sample and a second location for receiving a buffer solution. A first sorbent material is provided for directing a horizontal flow path for the sample. Means are provided for dividing the buffer solution received at the second location such that some of the buffer solution is directed to the first sorbent material which directs the sample, and some of the buffer solution is directed to a second sorbent material. In one embodiment, the second sorbent material takes an elongated path (e.g., curved, angled, or tortuous path) to the test zone which is located at the junction of the elongated path of the second sorbent material with the first sorbent material. In another embodiment, the second sorbent material is provided with a delay element along its length. In yet another embodiment, second and third sorbent materials are provided with the third sorbent material initially receiving the buffer solution and having a slower flow characteristic than the first sorbent material, and the second sorbent material in contact with the third sorbent material and forwarding the buffer solution to the test zone which is located at the junction of the second sorbent material and the first sorbent material. Regardless, conjugate is provided at a location along the second sorbent material. Preferably, the flow path provided by the first sorbent material is a direct path to the test zone. The test zone preferably includes one or more test lines or test sites with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc.


Where the test cell of the invention is provided in a housing, the housing is provided with a first opening adjacent the first location and a second opening adjacent the second location. A viewing window is provided in the housing above the test line.


Various means for dividing the buffer solution received at the second location are provided. A first means for dividing the buffer solution is a wedge element (V-shaped or triangular in cross-section) located at the location for receiving the buffer solution (e.g., an opening in a housing), where the apex of the V or triangle is directed upward. As drops of buffer solution are dropped into the buffer receiving opening, the apex divides the drops into two streams. The first stream is directed to the first sorbent material. The second stream is directed to the second elongated path sorbent material.


A second means for dividing the buffer solution received at the second location is a flow control material which is chosen to permit buffer to flow but which is resistant to receiving sample. The flow control material is coupled to both the first and second sorbent materials.


A third means for dividing the buffer solution received at the second location is an arrangement where the second location is an opening in a housing sized to receive the nib of a buffer dispenser, and a vertical wall recessed in the housing opening is provided to divide the buffer solution. Preferably, the first sorbent material is provided on one side of the vertical wall, and the second sorbent material is provided on the other side of the vertical wall.


According to one aspect of the invention, the means for dividing the buffer solution may be arranged so that approximately half of the buffer solution is directed toward the first sorbent material and the other half of the buffer solution is directed toward the second sorbent material.


According to another aspect of the invention, the means for dividing the buffer solution may be arranged so that a desired first proportion of the buffer solution is directed toward the first sorbent material and a desired different second proportion of the buffer solution is directed toward the second sorbent material.


In one embodiment, the locations for receiving the sample and the buffer solution are near or adjacent each other.


In the preferred embodiment of the invention, the first sorbent material and second sorbent material are separate pieces which overlie one another at the test site junction, and the test line is printed on one or both of the sorbent materials at the junction. The systems of the invention preferably also include a control line or site which may be seen from the viewing window.


According to one aspect of the invention, a test cell as summarized above may be used by (1) depositing a sample at the (first) location for receiving the sample, (2) depositing buffer solution at the (second) location for receiving the buffer solution, and (3) after a desired period of time, inspecting the test zone to determine whether the test is positive or negative. It is noted that sufficient buffer is deposited at the second location to cause the sample to move along the first sorbent material to the test zone, as well as to traverse the path of the second (and where provided, third) sorbent material and cause the conjugate to move to the test zone. Because of the arrangement of the first sorbent material as well as the second (and where provided, third) sorbent material, the sample is brought to the test zone in advance of the conjugate.


In one embodiment of the invention, the materials, thicknesses and lengths of the first and second sorbent materials are chosen to adjust the timing regarding the sample and conjugate reaching the test site.


In a fourth generation assay, two paths are provided for directing sample to two test zones, and two elongated paths are provided for carrying buffer and conjugate to the test zones. A first test zone is provided at the intersection of one of the elongated paths with one of the two sample paths, and a second test zone is provided at an intersection of the other elongated path and the second of the sample paths. In the fourth generation assay, one of the test zones may test for antigens in the sample while the other of the test zones may test for antibodies in the sample.


Additional objects and advantages of the invention will become apparent to those skilled in the art upon reference to the detailed description taken in conjunction with the provided figures.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic view of a first embodiment of the invention.



FIG. 2 is a schematic view of a second embodiment of the invention.



FIG. 3
a is a schematic view of a third embodiment of the invention.



FIG. 3
b is a schematic view of an alternative third embodiment of the invention.



FIG. 4 is a schematic view of a fourth embodiment of the invention.



FIG. 5 is a schematic view of a fifth embodiment of the invention.



FIG. 6 is a schematic view of a sixth embodiment of the invention.



FIG. 7 is a side view of a first embodiment of a buffer divider.



FIG. 8 is a top view of a second embodiment of a buffer divider.



FIG. 9 is a top view of a third embodiment of a buffer divider without the dropper.



FIG. 9
a is a side view of the third embodiment of the buffer divider.



FIG. 10 is a cross-sectional view of a buffer button.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Before turning to the Figures, the previously incorporated applications are noted as providing examples of dual path immunoassay devices relevant to the present invention. In particular, many of the same elements described in the embodiments of the previously incorporated applications are utilized as the building blocks for the embodiments of the invention which are further described below. As a result, details of those elements are not further described, and attention may be paid to those applications for those details.


Turning now to FIG. 1, a first embodiment of a dry conjugate dual path immunoassay device system 1000 is provided. System 1000 and includes a test cell 1010 with a first location 1026 for receiving a sample and a second location 1024 for receiving a buffer solution. A first sorbent or bibulous material 1032 is provided for directing a horizontal flow path 1061 for the sample. Means discussed below with reference to FIGS. 7-9b are provided for dividing the buffer solution received at the second location 1024 such that some of the buffer solution is directed to the first sorbent material 1032 which directs the sample, and some of the buffer solution is directed to a second sorbent or bibulous material 1030. In the embodiment of FIG. 1, the second sorbent material 1030 is seen to take an elongated path 1062 to the test zone 1033 which is located at the junction of the elongated path of the second sorbent material 1030 with the first sorbent material 1032. The test zone 1033 includes one or more test lines or indicators (e.g., 1050A, 1050B) having immobilized antigens or antibodies on either sorbent material 1030 or sorbent material 1032. Preferably, a control line 1060 is provided downstream of the test line(s), and an optional reservoir or wicking zone 1037 may be provided as well. Conjugate 1039 having desired antigens or antibodies with attached colored markers is immobilized along the elongated path 1062 in or on the second sorbent material 1030 upstream of the test zone 1033. As shown in FIG. 1, the conjugate 1039 is preferably located toward the test zone end of the elongated path. The elongated path 1062 of the second sorbent material 1030 of FIG. 1 is shown to be tortuous and more than five times the length of the horizontal flow path 1061 for the sample. In this manner, if sample is first deposited into the first location 1026, and buffer is then deposited in the second location 1024, the buffer will cause the sample to reach the test zone 1033 via path 1061 and permit antigens or antibodies in the sample to bind to the antibodies or antigens in the test lines 1050A, 1050B in advance of the conjugate 1039 being carried by buffer reaching the test zone via the elongated path 1062.


A second embodiment of a dry conjugate dual path immunoassay device system 1100 is seen in FIG. 2. System 1100 and includes a test cell 1110 with a first location 1126 for receiving a sample and a second location 1124 for receiving a buffer solution. A first sorbent or bibulous material 1132 is provided for directing a horizontal flow path 1161 for the sample. Means discussed below with reference to FIGS. 7-9b are provided for dividing the buffer solution received at the second location 1124 such that some of the buffer solution is directed to the first sorbent material 1132 which directs the sample, and some of the buffer solution is directed to a second sorbent or bibulous material 1130. In the embodiment of FIG. 2, the second sorbent material 1130 is seen to take an elongated path 1162 to the test zone 1133 which is located at the junction of the elongated path of the second sorbent material 1130 with the first sorbent material 1132. The test zone 1133 includes one or more test lines or indicators (e.g., 1150A, 1150B) having immobilized antigens or antibodies on either sorbent material 1130 or sorbent material 1132. Preferably, a control line 1160 is provided downstream of the test line(s), and an optional reservoir or wicking zone 1137 may be provided as well. Conjugate 1139 having desired antigens or antibodies with attached colored markers is immobilized along the elongated path 1162 in or on the second sorbent material 1130 upstream of the test zone 1133. As shown in FIG. 1, the conjugate 1139 is preferably located toward the test zone end of the elongated path. The elongated path 1162 of the second sorbent material 1130 of FIG. 1 is shown to be curved and approximately four times the length of the horizontal flow path 1161 for the sample. In this manner, if sample is first deposited into the first location 1126, and buffer is then deposited in the second location 1124, the buffer will cause the sample to reach the test zone 1133 via path 1161 and permit antigens or antibodies in the sample to bind to the antibodies or antigens in the test lines 1150A, 1150B in advance of the conjugate 1139 being carried by buffer reaching the test zone via the elongated path 1162.


Alternate third embodiments of a dry conjugate dual path immunoassay device system 1200a, 1200b are seen in FIGS. 3a and 3b. The alternate third embodiments are similar to the second embodiment system 1100 except that the instead of providing elongated paths 1262a, 1262b for the buffer which are approximately four times the length of the sample paths 1261a, 1261b, the curved paths 1262a, 1262b are about twice as long as the sample paths, but are provided with a delay element 1295a, 1295b along their lengths. In the embodiment of FIG. 3a, the delay element 1295a is a narrowing or bottleneck in the flow path which limits the flow capacity therethrough. In the embodiment of FIG. 3b, the delay element 1295b is a viscous material (e.g., sugar) or a blocking agent (e.g., BSA—bovine serum albumin). Delay element 1295b is utilized to delay the flow of buffer along the second sorbent material 1230a, 1230b such that buffer deposited into the second location 1216a, 1216b (and divided by means discussed below with reference to FIGS. 7-9b) will cause the sample deposited into the first location 1226a, 1226b to reach the test zone 1233a, 1233b via path 1261a, 1261b and permit antigens or antibodies in the sample to bind to the antibodies or antigens in the test line 1250a, 1250b in advance of the conjugate 1239a, 1239b being carried by buffer reaching the test zone via the elongated path 1262a, 1262b which includes the delay element 1295a, 1295b. In addition, if desired, multiple delay elements may be provided along the second sorbent material. The alternate third embodiments also preferably include control lines in zones 1250a, 1250b and wicking zones 1237a, 1237b.


A fourth embodiment of a dry conjugate dual path immunoassay device system 1300 is seen in FIG. 4. The fourth embodiment is similar to the alternate third embodiment systems 1200a, 1200b except that the instead of providing a delay element along the length second sorbent or bibulous material, a third sorbent or bibulous material 1330A is provided between the second receiving location 1324 and the second sorbent material 1330. The third sorbent material 1330A is selected to have a slower flow characteristic than either the first sorbent material 1332 or the second sorbent material 1330. The conjugate material 1339 is preferably located along the second sorbent material 1330, although it could be located along the third sorbent material 1330A. The test zone 1333 with one or more test lines 1350A, 1350B is located at the intersection of the first sorbent material 1332 and the second sorbent material 1330, and a control zone 1360 with a control indicator as well as a wicking zone 1337 are preferably provided downstream of the test zone 1333. With the provided arrangement, if sample is first deposited into the first location 1326, and buffer is then deposited in the second location 1324 (and divided by means discussed below with reference to FIGS. 7-9b), the buffer will cause the sample to reach the test zone 1333 via path 1361 and permit antigens or antibodies in the sample to bind to the antibodies or antigens in the test lines 1350A, 1350B in advance of the conjugate 1339 being carried by buffer reaching the test zone via the elongated path 1362 which includes the third sorbent material 1330A and the second sorbent material 1330.


A fifth embodiment of a dry conjugate dual path immunoassay device system 1400 is seen in FIG. 5 and provides a fourth generation immunoassay device. The fifth embodiment is similar to the fourth embodiment except that two separate samples are established, two elongated paths are established for the buffer (and conjugate), and two test zones are established; typically, one for testing antigens and the other for testing antibodies. More particularly, system 1400 includes a includes a test cell 1410 with a first location 1426 for receiving a sample and a second location 1424 for receiving a buffer solution. A first sorbent or bibulous material 1432a, 1432b is provided for directing horizontal flow paths 1461a, 1461b for the sample. The first sorbent material may be made from a single piece of material or multiple pieces of material. Means discussed below with reference to FIGS. 7-9b are provided for dividing the buffer solution received at the second location 1124 such that some of the buffer solution is directed to the first sorbent material 1432a, 1432b which directs the sample, and some of the buffer solution is directed to the third sorbent or bibulous material 1430A (selected to have a slower flow characteristic than either the first sorbent material 1432a, 1432b or the second or fourth sorbent material 1430a, 1430b). In the embodiment of FIG. 5, the third sorbent material 1430A is arranged as a “T”, although the material could be formed into other shapes (such as a “V”, an “M”, or a dash, by way of example only). Regardless, the third sorbent material 1430A is in contact with second sorbent material 1430a, 1430b (shown as two separate pieces in FIG. 5—although depending upon the arrangement of the third sorbent material, the second sorbent material could be a single piece such as in the shape of a bracket ([), an “E”, by way of example only). This provides two elongated path 1462a, 1462b to the respective test zones 1433a, 1433b which are respectively located at the junction of the second sorbent material 1430a with the first sorbent material 1432a, and the junction of the second sorbent material 1430b with the first sorbent material 1432b. The test zones 1433a, 1433b include one or more test lines or indicators (e.g., 1450A, 1450B) having immobilized antigens or antibodies on either sorbent material 1430a, 1430b or sorbent material 1432a, 1432b. Preferably, control lines 1460a, 1460b is provided downstream of the test lines, and an optional reservoir or wicking zone 1437a, 1437b may be provided as well. Conjugate 1439a, 1439b having desired antigens or antibodies with attached colored markers is immobilized along the elongated paths 1462a, 1462b preferably in or on the second sorbent material 1430a, 1430b upstream of the test zones 1433a, 1433b. As shown in FIG. 5, the conjugate zones are preferably located toward the test zone ends of the elongated paths. With the provided arrangement, if sample is first deposited into the first location 1426, and buffer is then deposited in the second location 1424, the buffer will cause the sample to reach the test zones 1433a, 1433b via paths 1461a, 1461b and permit antigens and/or antibodies in the sample to bind to the antibodies and/or antigens in the test lines 1450A, 1450B in advance of the conjugate 1439a, 1439b being carried by buffer reaching the test zone via the elongated paths 1462a, 1462b.


In the fourth and fifth embodiments, the third sorbent or bibulous material which has a slower flow characteristic relative to the first sorbent material may be a small pore membrane (e.g., nitrocellulose or nylon membrane having a pore size of 3 to 30 microns), glass fibers, or cellulose, polyester, rayon or other known synthetic materials. As will be appreciated by those skilled in the art, other materials could be utilized to control the speed of the buffer flow through the third sorbent material and thereby control arrival timing of the buffer with the conjugate at the test site relative to the arrival of the sample.


A sixth embodiment of a dry conjugate dual path immunoassay device system 1500 is seen in FIG. 6 and also provides a fourth generation immunoassay device. The sixth embodiment is similar to the fifth embodiment except that instead of providing a third sorbent material having slower flow characteristics, the elongated paths for the buffer which eventually carries the conjugate are tortuous or serpentine, and are at least five times the length of the sample flow path. More particularly, system 1500 includes a includes a test cell 1510 with a first location 1526 for receiving a sample and a second location 1524 for receiving a buffer solution. A first sorbent or bibulous material with branches 1532a, 1532b is provided for directing horizontal flow paths 1561a, 1561b for the sample. The first sorbent material may be made from a single piece of material or multiple pieces of material. Means discussed below with reference to FIGS. 7-9b are provided for dividing the buffer solution received at the second location 1524 such that some of the buffer solution is directed to the first sorbent material 1532a, 1532b which directs the sample, and some of the buffer solution is directed to the second sorbent or bibulous material 1530a 1530b which provides two elongated path branches 1562a, 1562b to the respective test zones 1533a, 1533b which are respectively located at the junction a first branch of the second sorbent material 1530a with a first branch of the first sorbent material 1532a, and the junction of a second branch of the second sorbent material 1530b with a second branch of the first sorbent material 1532b. The test zones 1533a, 1533b include one or more test lines or indicators (e.g., 1550A, 1550B) having immobilized antigens or antibodies on either sorbent material 1530a, 1530b or sorbent material 1532a, 1532b. Preferably, control lines 1560a, 1560b is provided downstream of the test lines, and an optional reservoir or wicking zone 1537a, 1537b may be provided as well. Conjugate 1539a, 1539b having desired antigens or antibodies with attached colored markers is immobilized along the elongated paths 1562a, 1562b preferably in or on the second sorbent material 1530a, 1530b upstream of the test zones 1533a, 1533b. As shown in FIG. 6, the conjugate zones are preferably located toward the test zone ends of the elongated paths. With the provided arrangement, if sample is first deposited into the first location 1526, and buffer is then deposited in the second location 1524, the buffer will cause the sample to reach the test zones 1533a, 1533b via paths 1561a, 1561b and permit antigens and/or antibodies in the sample to bind to the antibodies and/or antigens in the test lines 1550A, 1550B in advance of the conjugate 1539a, 1539b being carried by buffer reaching the test zone via the elongated paths 1562a, 1562b.


In all the previous embodiments, where the test cell of the invention is provided in a housing, the housing is provided with a first opening adjacent the first location and a second opening adjacent the second location. A viewing window is provided in the housing above the test line. Where a control line is provided, the viewing window may extend over the test line and control line, or a separate viewing window may be provided over the control line.


In all of the previous embodiments, it is preferred that the locations for receiving the sample and the buffer solution are provided near or adjacent each other.


Turning now to FIGS. 7-9b, various dividers which divide the buffer solution received at the second location are provided. A first divider for the buffer solution is seen in FIG. 7 and comprises a wedge-shaped element 1601 (V-shaped or triangular in cross section) located at the location for receiving the buffer solution (e.g., at an opening in a housing), where the apex 1602 of the wedge is directed upward. As drops of buffer solution are dropped into the buffer receiving opening, the apex divides the drops into two streams. The first stream is directed to the first sorbent material. The second stream is directed to the second elongated path sorbent material. If the wedge apex is located in the middle of the buffer receiving location, half of the buffer solution is directed toward the sample receiving location and first sorbent material, and the other half is directed toward the second sorbent material. If the wedge apex is located to one side or the other, more of the buffer may be directed one way or to the other.


A second divider for the buffer solution received at the second location is shown in FIG. 8 and comprises a flow control material 1601a. Flow control material 1601a is chosen to permit buffer to flow but is resistant to receiving sample. An example would be a very small pore size material such as cotton or cellulose paper (preferably with pores less than 3 microns). The flow control material 1601a is coupled to both the sample receiving location (e.g., pad) and the second (or third) sorbent material.


A third divider 1601b for the buffer solution received at the second location is shown in FIGS. 9 and 9a and comprises an opening 1603 in a housing 1604 sized to receive the nib 1605 of a buffer dispenser, and a vertical wall 1606 recessed in the housing opening which divides the buffer solution. Preferably, the sample receiving location or pad is provided on one side of the vertical wall, and the second (or third) sorbent material is provided on the other side of the vertical wall. It will be appreciated that the wall 1606 can take any desired shape as long as it is located appropriately to divide drops of buffer being delivered by the buffer dispenser nib. Thus wall may divide the buffer solution so that approximately half of the buffer solution is directed toward the first sorbent material and the other half of the buffer solution is directed toward the second sorbent material, or may divide the buffer solution so that a desired first proportion of the buffer solution is directed toward the first sorbent material and a desired different second proportion of the buffer solution is directed toward the second sorbent material.


With respect to all of the above test cell embodiments and buffer divider embodiments, if desired, the buffer may be packaged as part of the test cell by providing a “buffer button” 1780 as seen in FIG. 10 at the second location. For example, if a housing is provided, the buffer button may constitute a module located in a housing opening above the second location. The module could constitute a flexible plastic upper member 1781 and a rupturable (e.g., foil or plastic) lower member 1782, with the buffer solution 1783 contained therebetween. As a result, when the flexible plastic upper member is pressed, the force is translated to the buffer solution which causes the lower member to rupture and release the buffer solution which is then divided by the buffer dividing means. Alternatively, contained within the module may be a dividing element (e.g., a vertical plastic element connected to the flexible plastic upper member) which causes the lower container to rupture and which will automatically divide the buffer solution contained within the module without need for a separate means for dividing the buffer solution. As another alternative, a wedge (such as wedge 1600) or a wall (such as wall 1606) contained within the housing below the buffer button can be used to rupture the lower member when the buffer button is pressed.


According to one aspect of the invention, any of the test cells described above may be used by (1) depositing a sample at the (first) location for receiving the sample, (2) depositing a predetermined amount of buffer solution at the (second) location for receiving the buffer solution, and (3) after a desired period of time, inspecting the test zone(s) and where provided the control zone(s) to determine whether the test is positive or negative. It is noted that sufficient buffer is deposited at the second location to cause the sample to move along the first sorbent material to the test zone, as well as to traverse the path of the second (and where provided, third) sorbent material and cause the conjugate to move to the test zone. Because of the arrangement of the first sorbent material as well as the second (and where provided, third) sorbent material, the sample is brought to the test zone in advance of the conjugate. The step of depositing a sample may involve depositing blood, serum, spittum, feces, or other bodily fluid at the first location via a dropper, a swab, a loop or other depositing means known in the art. The step of depositing a predetermined amount of buffer solution may comprise utilizing a dropper, pressing a buffer button, or utilizing any other depositing means known in the art.


It will be appreciated that the materials, thicknesses and lengths of the first and second sorbent materials are chosen to adjust the timing regarding the sample and conjugate reaching the test site(s).


There have been described and illustrated herein several embodiments of immunoassays and methods of their use. While particular embodiments of the invention have been described, it is not intended that the invention be limited thereto, as it is intended that the invention be as broad in scope as the art will allow and that the specification be read likewise. For example, while the specification discusses ligand binding using antigen/antibody reactions, other ligand binding mechanisms such as aptamer binding, nucleic acid binding, enzymatic binding, etc. may also be used. Also while particular buffer dividers have been described which divide the buffer for the sample flow path and the conjugate flow path, it will be appreciated that other dividers could be utilized. Further, it should be appreciated that chemical agents such as sugar, BSA, detergent, etc., or biological agents (serum, antibody, antigen) may be added in one or both of the sorbent strips in order to delay or enhance flow rate for the buffer or for the buffer/sample solution. These modifications could be additionally utilized to enhance sensitivity or block non-specific binding for the assay. It will therefore be appreciated by those skilled in the art that yet other modifications could be made to the provided invention without deviating from its spirit and scope as claimed.

Claims
  • 1. A test device for determining the presence of a ligand in a sample, comprising: a) buffer solution;b) a first sorbent strip having a first location for receiving a sample and defining a first migration path;c) a second sorbent strip distinct from said first sorbent strip, said second sorbent strip having a second location for receiving said buffer solution and at least partially defining a second migration path distinct from said first migration path and elongated relative to said first migration path;d) a conjugate supported by said second sorbent strip;e) a test site located on or in at least one of said first sorbent strip and said second sorbent strip, said test site having an immobilized ligand-binding mechanism, and said first and second sorbent strips touching each other at the test site;f) a frangible container and divider located at said second location, said frangible container containing said buffer solution, said divider directing a first amount of said buffer solution to said first sorbent strip to move said sample to said test site and a second amount to said second sorbent strip to move said conjugate to said test site upon breaking of said frangible container; andg) a housing defining a first opening adjacent said first location, a second opening adjacent said second location, and a window adjacent said test site through which said test site is viewable, wherein said first migration path is provided with a first length and said second migration path is provided with a second length, and said first length said second length are chosen to permit said sample to reach said test site so that ligand in said sample reaches said test site and binds to said immobilized ligand-binding mechanism prior to said conjugate reaching said test site.
  • 2. A test device according to claim 1, wherein: said second migration path is tortuous.
  • 3. A test device according to claim 2, wherein: said second migration path is at least four times as long as said first migration path.
  • 4. A test device according to claim 1, wherein: said second sorbent strip includes a delay element.
  • 5. A test device according to claim 1, further comprising: a third sorbent strip distinct from said first sorbent strip and said second sorbent strip, said third sorbent strip coupling said second location to said second sorbent strip, said third sorbent strip having slower flow characteristics than said first sorbent material.
  • 6. A test device according to claim 1, wherein: said conjugate comprises an antigen or antibody for the ligand and a marker coupled to the antigen or antibody.
  • 7. A test device according to claim 6, wherein: said marker is a colored marker viewable in the visible spectrum.
  • 8. A test device according to claim 1, wherein: said at least one of said first and second sorbent strips includes a control site, and said housing defines a window for viewing said control site.
  • 9. A test device according to claim 1, wherein: said first sorbent strip has a first pore size and said second sorbent strip has a second pore size, and said first pore size is larger than said second pore size.
  • 10. A test device according to claim 9, wherein: said first pore size is between 3 and 20 microns, andsaid second pore size is between 20 and 40 microns.
  • 11. A test device according to claim 1, wherein: said divider comprises a wedge or a wall.
  • 12. A test device according to claim 1, wherein: said second location is adjacent said first location.
  • 13. A method for testing a sample for the presence of a ligand, comprising: a) obtaining a test device according to claim 1;b) applying the sample to said first location;c) after said applying the sample, applying the buffer solution to the second location by breaking the frangible container; andd) inspecting said test site to determine an indication the presence or lack thereof of the ligand in the sample.
  • 14. A test device for determining the presence of a ligand in a sample, said test device for use with a buffer solution and comprising: a) a first sorbent or bibulous material having a first location for receiving a sample and defining a first horizontal migration path for the sample;b) a second sorbent or bibulous material in fluid contact with said first location and defining a second horizontal migration path for the sample;c) a third sorbent or bibulous material distinct from said first and second sorbent or bibulous materials, said third sorbent or bibulous material receiving the buffer solution and at least partially defining a third horizontal migration path distinct from said first and second migration paths and elongated relative to said first and second migration paths;d) a first conjugate supported by said third sorbent or bibulous material;e) a fourth sorbent or bibulous material distinct from said first and second sorbent or bibulous materials, said fourth sorbent or bibulous material receiving the buffer solution and at least partially defining a fourth horizontal migration path distinct from said first and second migration paths and elongated relative to said first and second migration paths;f) a second conjugate supported by said fourth sorbent or bibulous material;g) a first test site located on or in at least one of said first sorbent or bibulous material and said third sorbent or bibulous material, said first test site having a first immobilized ligand-binding mechanism for detecting antibodies in the sample, and said first and third sorbent or bibulous materials touching each other at said first test site;h) a second test site located on or in at least one of said second sorbent or bibulous material and said fourth sorbent or bibulous material, said second test site having a second immobilized ligand-binding mechanism for detecting antigens in the sample, said second and fourth sorbent or bibulous materials touching each other at said second test site; andi) a divider which directs a first amount of said buffer solution to said first and second sorbent or bibulous materials to move said sample to said first and second test sites and a second amount of said buffer solution to said third and fourth sorbent or bibulous materials to move said first and second conjugates to said first and second test sites, wherein said first migration path is provided with a first length, said second migration path is provided with a second length, said third migration path is provided with a third length, and said fourth migration path is provided with a fourth length, and said first length and said third length are chosen to permit said sample to reach said first test site so that ligand in said sample reaches said first test site and binds to said first immobilized ligand-binding mechanism prior to said first conjugate reaching said first test site, and said second length and said fourth length are chosen to permit said sample to reach said second test site so that ligand in said sample reaches said second test site and binds to said second immobilized ligand-binding mechanism prior to said second conjugate reaching said second test site.
  • 15. A test device according to claim 14, further comprising: a fifth sorbent or bibulous material distinct from said first, second, third and fourth sorbent or bibulous materials, said third fifth sorbent or bibulous material coupling said second location to said third sorbent or bibulous material, said fifth sorbent or bibulous material having slower flow characteristics than said first sorbent or bibulous material.
  • 16. A test device according to claim 15, further comprising: a sixth sorbent or bibulous material distinct from said first, second, third and fourth sorbent or bibulous strips, said sixth sorbent or bibulous material coupling said second location to said third sorbent or bibulous strip, said fifth sorbent or bibulous material having slower flow characteristics than said second sorbent or bibulous material.
  • 17. A test device according to claim 16, wherein: said fifth and sixth sorbent or bibulous materials have portions which are not distinct from each other.
  • 18. A method according for testing a sample for the presence ligands, comprising: a) obtaining a test device according to claim 14;b) applying the sample to said first location;c) after said applying the sample, applying the buffer solution to the second location; andd) inspecting said first and second test sites to determine an indication the presence or lack thereof of the ligands in the sample.
  • 19. A method according to claim 18, wherein: said test device has a housing defining a first opening adjacent said first location, a second opening adjacent said second location, a first window adjacent said first test site through which said first test site is viewable, and a second window adjacent said second test site through which said second test site is viewable;said applying the sample comprises depositing the sample through said first opening to said first location,said applying the solution comprises depositing the buffer solution through said second opening to said second location, andsaid inspecting comprises inspecting through said first window and through said second window.
US Referenced Citations (372)
Number Name Date Kind
3960488 Giaever Jun 1976 A
4041146 Giaever Aug 1977 A
4042335 Clement Aug 1977 A
4059405 Sodickson et al. Nov 1977 A
4094647 Deutsch et al. Jun 1978 A
4144306 Figueras Mar 1979 A
4235601 Deutsch et al. Nov 1980 A
4313734 Leuvering Feb 1982 A
4323536 Columbus Apr 1982 A
4361537 Deutsch et al. Nov 1982 A
4366241 Tom et al. Dec 1982 A
4373932 Gribnau Feb 1983 A
4522786 Ebersole Jun 1985 A
4532107 Siddigi Jul 1985 A
4588555 Provonchee May 1986 A
4595654 Reckel et al. Jun 1986 A
4632901 Valkirs et al. Dec 1986 A
4668619 Greenquist et al. May 1987 A
4703017 Campbell et al. Oct 1987 A
4740468 Weng et al. Apr 1988 A
4770853 Bernstein Sep 1988 A
4786595 Arai et al. Nov 1988 A
4826759 Guire et al. May 1989 A
4855240 Rosenstein et al. Aug 1989 A
4857453 Ullman et al. Aug 1989 A
4870003 Kortright et al. Sep 1989 A
4886742 Kortright et al. Dec 1989 A
4906439 Grenner Mar 1990 A
4912034 Kalra et al. Mar 1990 A
4920046 McFarland et al. Apr 1990 A
4943522 Eisinger et al. Jul 1990 A
4956275 Zuk et al. Sep 1990 A
4956302 Gordon et al. Sep 1990 A
4960691 Gordon et al. Oct 1990 A
4960710 Lau Oct 1990 A
4981785 Nayak Jan 1991 A
4981786 Dafforn et al. Jan 1991 A
5004584 Rayman Apr 1991 A
5006464 Chu et al. Apr 1991 A
5006474 Horstman et al. Apr 1991 A
5075077 Durley, III et al. Dec 1991 A
5087556 Ertinghausen Feb 1992 A
5091153 Bachand Feb 1992 A
5104793 Buck Apr 1992 A
5104811 Berger et al. Apr 1992 A
5110550 Schlipfenbacher May 1992 A
5132208 Freitag et al. Jul 1992 A
5137808 Ullman et al. Aug 1992 A
5147780 Pouletty et al. Sep 1992 A
5156952 Litman et al. Oct 1992 A
5162238 Eikmeier et al. Nov 1992 A
5169789 Bernstein Dec 1992 A
5173433 Bachand Dec 1992 A
5200321 Kidwell Apr 1993 A
5202268 Kuhn et al. Apr 1993 A
5215446 Takahashi Jun 1993 A
5217905 Marchand et al. Jun 1993 A
5219762 Katamine et al. Jun 1993 A
5223436 Freitag et al. Jun 1993 A
RE34312 Geiger et al. Jul 1993 E
5232835 Litman et al. Aug 1993 A
5238649 Nason Aug 1993 A
5240735 Lau Aug 1993 A
5244631 Morikawa Sep 1993 A
5244788 Hubscher Sep 1993 A
RE34405 Gould et al. Oct 1993 E
5252496 Kang et al. Oct 1993 A
5275785 May et al. Jan 1994 A
5281540 Merkh et al. Jan 1994 A
5296192 Carroll et al. Mar 1994 A
5300439 Charlton Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5308775 Donovan et al. May 1994 A
5332548 Moore Jul 1994 A
5334502 Sangha Aug 1994 A
5338513 Schlipfenbacher Aug 1994 A
5340748 Baugher et al. Aug 1994 A
5356782 Moorman et al. Oct 1994 A
5362654 Pouletty Nov 1994 A
5369007 Kidwell Nov 1994 A
5384264 Chen et al. Jan 1995 A
5391478 Greene et al. Feb 1995 A
5399316 Yamada Mar 1995 A
5411858 McGeeham et al. May 1995 A
5418136 Miller et al. May 1995 A
5418142 Kiser et al. May 1995 A
5418167 Matner et al. May 1995 A
5424215 Albarella et al. Jun 1995 A
5424220 Goerlach-Graw et al. Jun 1995 A
5435970 Mamenta et al. Jul 1995 A
5451504 Fitzpatrick et al. Sep 1995 A
5468648 Chandler Nov 1995 A
5470713 El Shami et al. Nov 1995 A
5474902 Uylen et al. Dec 1995 A
5482830 Bogart et al. Jan 1996 A
5494830 Hubscher Feb 1996 A
5500350 Baker et al. Mar 1996 A
5501985 Baugher et al. Mar 1996 A
5514557 Moghaddam May 1996 A
5521102 Boehringer et al. May 1996 A
5532133 Barnwell Jul 1996 A
5541057 Bogart et al. Jul 1996 A
5550063 Bogart Aug 1996 A
5552272 Bogart Sep 1996 A
5558834 Chu et al. Sep 1996 A
5559041 Kang et al. Sep 1996 A
5567594 Calenoff Oct 1996 A
5571667 Chu et al. Nov 1996 A
5591645 Rosenstein Jan 1997 A
5602040 May et al. Feb 1997 A
5604110 Baker et al. Feb 1997 A
5607863 Chandler Mar 1997 A
5616467 Olsen et al. Apr 1997 A
5620845 Gould et al. Apr 1997 A
5622871 May et al. Apr 1997 A
5624809 Skold et al. Apr 1997 A
5629164 Rivers May 1997 A
5629214 Crosby May 1997 A
5639671 Bogart et al. Jun 1997 A
5641639 Perry Jun 1997 A
5648274 Chandler Jul 1997 A
5656503 May et al. Aug 1997 A
5658723 Oberhardt Aug 1997 A
5658801 Poissant et al. Aug 1997 A
5670381 Jou et al. Sep 1997 A
5686315 Pronovost Nov 1997 A
5695928 Stewart et al. Dec 1997 A
5695930 Weinstein et al. Dec 1997 A
5710005 Rittenburg Jan 1998 A
5714341 Thieme et al. Feb 1998 A
5714389 Charlton et al. Feb 1998 A
5723345 Yamauchi et al. Mar 1998 A
5726010 Clark Mar 1998 A
5728587 Kang et al. Mar 1998 A
5736188 Alcock et al. Apr 1998 A
5739041 Nazareth et al. Apr 1998 A
5743960 Tisone Apr 1998 A
5750333 Clark May 1998 A
5766961 Pawlak et al. Jun 1998 A
5766962 Childs et al. Jun 1998 A
5770460 Pawlak et al. Jun 1998 A
5773234 Pronovost et al. Jun 1998 A
5786220 Pronovost et al. Jul 1998 A
5807756 Bauman et al. Sep 1998 A
5814522 Zimmer et al. Sep 1998 A
5824268 Bernstein et al. Oct 1998 A
5827646 Middeldorp et al. Oct 1998 A
5846838 Chandler Dec 1998 A
5853670 Bunce Dec 1998 A
5861265 Perry Jan 1999 A
5869272 Bogart et al. Feb 1999 A
5869345 Chandler Feb 1999 A
5872713 Douglas et al. Feb 1999 A
5874216 Mapes Feb 1999 A
5877028 Chandler et al. Mar 1999 A
5879951 Sy Mar 1999 A
5885526 Chu Mar 1999 A
5885527 Buechler Mar 1999 A
5891650 Godowski et al. Apr 1999 A
5900379 Noda et al. May 1999 A
5902722 Di Cesare et al. May 1999 A
5912116 Caldwell Jun 1999 A
5922533 Vallari et al. Jul 1999 A
5922615 Nowakowski et al. Jul 1999 A
5935331 Naka et al. Aug 1999 A
5939252 Lennon et al. Aug 1999 A
5939272 Buechler et al. Aug 1999 A
5948695 Douglas et al. Sep 1999 A
5955377 Maul et al. Sep 1999 A
5958790 Cerny Sep 1999 A
5965458 Kouvonen et al. Oct 1999 A
5972720 Nichtl et al. Oct 1999 A
5976895 Cipkowski Nov 1999 A
5985675 Charm et al. Nov 1999 A
5989921 Charlton et al. Nov 1999 A
5998220 Chandler Dec 1999 A
5998221 Malick et al. Dec 1999 A
6008056 Thieme Dec 1999 A
6017767 Chandler Jan 2000 A
6027890 Ness et al. Feb 2000 A
6040195 Carroll et al. Mar 2000 A
6046013 Tidey et al. Apr 2000 A
6046057 Nazareth et al. Apr 2000 A
6057166 Childs et al. May 2000 A
6060326 Frank et al. May 2000 A
6063337 Markart May 2000 A
6087184 Magginetti et al. Jul 2000 A
6106732 Johnston et al. Aug 2000 A
6140134 Rittenburg Oct 2000 A
6140136 Lee Oct 2000 A
6168956 Chandler Jan 2001 B1
6187268 Albarella et al. Feb 2001 B1
6187598 May et al. Feb 2001 B1
6194220 Malick et al. Feb 2001 B1
6197494 Oberhardt Mar 2001 B1
6221625 Ashihara et al. Apr 2001 B1
6221678 Chandler Apr 2001 B1
6224831 Stafford et al. May 2001 B1
6228660 May et al. May 2001 B1
6235464 Henderson et al. May 2001 B1
6248598 Bogema Jun 2001 B1
6258548 Buck Jul 2001 B1
6271040 Buechler Aug 2001 B1
6271045 Douglas et al. Aug 2001 B1
6271046 Chandler Aug 2001 B1
6277650 Nazareth et al. Aug 2001 B1
6284550 Carroll et al. Sep 2001 B1
6287875 Geisberg Sep 2001 B1
6297020 Brock Oct 2001 B1
6297060 Nowakowski et al. Oct 2001 B1
6300142 Andrewes et al. Oct 2001 B1
RE37437 Friesen et al. Nov 2001 E
6316205 Guan et al. Nov 2001 B1
6316264 Corey et al. Nov 2001 B1
6319676 Nazareth et al. Nov 2001 B1
6326214 Liu et al. Dec 2001 B1
6335205 Bausback Jan 2002 B1
6352862 Davis et al. Mar 2002 B1
6362008 Kohn et al. Mar 2002 B1
6368875 Geisberg Apr 2002 B1
6368876 Huang et al. Apr 2002 B1
6372514 Lee Apr 2002 B1
6372515 Casterlin et al. Apr 2002 B1
6372516 Sun Apr 2002 B1
6376195 Mapes Apr 2002 B1
6399398 Cunningham et al. Jun 2002 B1
6403383 Casterlin et al. Jun 2002 B1
6403384 Lea Jun 2002 B1
6406922 Casterlin et al. Jun 2002 B2
6413473 Bacon Jul 2002 B1
6413784 Lundsgaard et al. Jul 2002 B1
6436722 Clark et al. Aug 2002 B1
6455324 Douglas Sep 2002 B1
6472226 Barradine et al. Oct 2002 B1
6475805 Charm et al. Nov 2002 B1
6485982 Charlton Nov 2002 B1
6489129 Faatz et al. Dec 2002 B1
6492127 Goodell et al. Dec 2002 B2
6500629 Cleaver et al. Dec 2002 B1
6502766 Streutker et al. Jan 2003 B1
6503702 Stewart Jan 2003 B1
6503722 Valkirs Jan 2003 B1
6511814 Carpenter Jan 2003 B1
6514769 Lee Feb 2003 B2
6514773 Klein et al. Feb 2003 B1
6528321 Fitzgerald et al. Mar 2003 B1
6528322 Carlsson et al. Mar 2003 B1
6528323 Thayer et al. Mar 2003 B1
6528325 Hubscher et al. Mar 2003 B1
6534324 Zin Mar 2003 B1
6544474 Douglas Apr 2003 B2
6548309 Moore et al. Apr 2003 B1
6551842 Carpenter Apr 2003 B1
6592815 Zimmer Jul 2003 B1
6593085 Barnett et al. Jul 2003 B1
6602719 Carpenter Aug 2003 B1
6617116 Guan et al. Sep 2003 B2
6623955 Matner et al. Sep 2003 B2
6627459 Tung et al. Sep 2003 B1
6632681 Chu Oct 2003 B1
6645732 Faatz et al. Nov 2003 B2
6649418 Geisberg Nov 2003 B1
6656744 Pronovost et al. Dec 2003 B2
6656745 Cole Dec 2003 B1
6660469 Wright et al. Dec 2003 B1
6663833 Stave et al. Dec 2003 B1
6673628 Freitag et al. Jan 2004 B2
RE38430 Rosenstein Feb 2004 E
6686167 Bagaria Feb 2004 B2
6699722 Bauer et al. Mar 2004 B2
6703196 Klepp et al. Mar 2004 B1
6706539 Nelson et al. Mar 2004 B2
6713309 Anderson et al. Mar 2004 B1
6727073 Moore et al. Apr 2004 B1
6737277 Kang et al. May 2004 B1
6750031 Ligler et al. Jun 2004 B1
6753190 Okada et al. Jun 2004 B1
6767710 DiNello et al. Jul 2004 B2
6767714 Nazareth et al. Jul 2004 B2
6780651 Douglas et al. Aug 2004 B2
6790611 Lassen et al. Sep 2004 B2
6797481 Ullman et al. Sep 2004 B1
6808889 Fitzpatrick et al. Oct 2004 B2
6808937 Ligler et al. Oct 2004 B2
6812038 Mendel-Hartvig et al. Nov 2004 B1
6818180 Douglas et al. Nov 2004 B2
6818455 May et al. Nov 2004 B2
6824975 Hubscher et al. Nov 2004 B2
6824997 Moore et al. Nov 2004 B1
6828110 Lee et al. Dec 2004 B2
RE38688 Friesen et al. Jan 2005 E
6844200 Brock Jan 2005 B2
6846635 Anderson et al. Jan 2005 B1
6849414 Guan et al. Feb 2005 B2
6855561 Jerome et al. Feb 2005 B2
6863866 Kelly et al. Mar 2005 B2
6867051 Anderson et al. Mar 2005 B1
6887701 Anderson et al. May 2005 B2
6905835 Sorell Gomez et al. Jun 2005 B2
6924153 Boehringer et al. Aug 2005 B1
6927068 Simonson et al. Aug 2005 B2
6991940 Carroll et al. Jan 2006 B2
7018847 Mendel-Hartvig et al. Mar 2006 B2
7045342 Nazareth et al. May 2006 B2
7049130 Carroll et al. May 2006 B2
7109042 May et al. Sep 2006 B2
7189522 Esfandiari Mar 2007 B2
7270995 Matsushita et al. Sep 2007 B2
7682801 Esfabdiari Mar 2010 B2
7879597 Esfandiari Feb 2011 B2
20010012637 Casterlin et al. Aug 2001 A1
20010026942 Carpenter et al. Oct 2001 A1
20010026944 Chung et al. Oct 2001 A1
20010034068 Spivey et al. Oct 2001 A1
20010039057 Douglas et al. Nov 2001 A1
20010048893 Norris et al. Dec 2001 A1
20020001853 Obremski et al. Jan 2002 A1
20020015663 Goldstein et al. Feb 2002 A1
20020019062 Lea et al. Feb 2002 A1
20020031839 McNeirney et al. Mar 2002 A1
20020046614 Alley Apr 2002 A1
20020048819 Alley Apr 2002 A1
20020052050 Douglas et al. May 2002 A1
20020057991 Kelly et al. May 2002 A1
20020058330 Carroll et al. May 2002 A1
20020110803 Dhar et al. Aug 2002 A1
20020119497 Wild et al. Aug 2002 A1
20020142291 Bauer et al. Oct 2002 A1
20020155028 Wong Oct 2002 A1
20020172937 Dave et al. Nov 2002 A1
20020173050 DiNello et al. Nov 2002 A1
20020192839 Mink et al. Dec 2002 A1
20030045001 Burgess et al. Mar 2003 A1
20030118480 Kaylor et al. Jun 2003 A1
20030124740 Bachand Jul 2003 A1
20030138351 Etes et al. Jul 2003 A1
20030143639 Matsushita et al. Jul 2003 A1
20030180967 Shigetoh Sep 2003 A1
20040001767 Peters et al. Jan 2004 A1
20040087036 Chung et al. May 2004 A1
20040142495 Hartman et al. Jul 2004 A1
20040161859 Guo et al. Aug 2004 A1
20040184954 Guo et al. Sep 2004 A1
20040219694 Chittock et al. Nov 2004 A1
20040235189 Lu Nov 2004 A1
20040241779 Piasio et al. Dec 2004 A1
20040248322 Charlton Dec 2004 A1
20050074900 Morgan et al. Apr 2005 A1
20050079629 Guo et al. Apr 2005 A1
20050112779 Wei et al. May 2005 A1
20050112780 Song May 2005 A1
20050112782 Buechler May 2005 A1
20050130293 Blatt et al. Jun 2005 A1
20050130319 Biegelsen et al. Jun 2005 A1
20050136500 Yang et al. Jun 2005 A1
20050142032 Hoenes et al. Jun 2005 A1
20050164404 Marlborugh et al. Jul 2005 A1
20050170527 Boehringer et al. Aug 2005 A1
20050208677 Owens et al. Sep 2005 A1
20050227371 Gokhan Oct 2005 A1
20050244985 Freitag et al. Nov 2005 A1
20050244986 May et al. Nov 2005 A1
20060099719 Curcio May 2006 A1
20060121626 Imrich Jun 2006 A1
20060134803 Esfandiari Jun 2006 A1
20060166374 Hubscher Jul 2006 A1
20070020768 Rundstrom et al. Jan 2007 A1
20070184492 Wang et al. Aug 2007 A1
20070243630 Boehringer et al. Oct 2007 A1
20080318341 Esfandiari Dec 2008 A1
20090148933 Battrell et al. Jun 2009 A1
20120003727 Esfandiari Jan 2012 A1
Foreign Referenced Citations (8)
Number Date Country
19917093 Oct 2000 DE
10313158 Oct 2004 DE
0299359 Jan 1989 EP
1284422 Feb 2003 EP
05104052 Apr 1993 JP
WO8808534 Nov 1988 WO
WO2004084274 Sep 2004 WO
WO2005070324 Aug 2005 WO
Related Publications (1)
Number Date Country
20120208299 A1 Aug 2012 US